Real-Life Data of Neoadjuvant Chemotherapy in Breast Cancer: Aegean Region Experience

Atike Pınar Erdoğan; Ferhat Ekinci; Ahmet Özveren; Emine Bihter Eniseler; Bilgin Demir; Mustafa Şahbazlar

doi:10.58600/eurjther.20232902-347.y

Authors

Atike Pınar Erdoğan Manisa Celal Bayar University https://orcid.org/0000-0003-4859-7574
Ferhat Ekinci Şırnak State Hospital https://orcid.org/0000-0002-9317-942X
Ahmet Özveren Kent Hospital Oncology Center/ İzmir https://orcid.org/0000-0002-6432-5432
Emine Bihter Eniseler Manisa Celal Bayar University Medical Faculty, Department Of Internal Medicine / Manisa https://orcid.org/0000-0001-5638-1816
Bilgin Demir Atatürk State Hospital Medical Oncology Clinic / Aydın https://orcid.org/0000-0003-4380-9419
Mustafa Şahbazlar Manisa Celal Bayar University Medical Faculty, Department Of Internal Medicine Divison Of Medical Oncology/ Manisa https://orcid.org/0000-0003-1857-593X

DOI:

https://doi.org/10.58600/eurjther.20232902-347.y

Keywords:

breast neoplasms, developing countries, neoadjuvant therapy, pathologic response

Abstract

Objective: The use of neoadjuvant chemotherapy (NACT) in breast cancer is increasing. The management of locally advanced breast cancer differs due to the approach of the center to which the patient applied and the approach of the following physician. From this point of view, we aimed to evaluate the real life data of our region.

Methods: The study included 106 patients treated with neoadjuvant chemotherapy in the medical oncology clinic of two different university hospitals. Association between clinicopathological features and pathological complete response (pCR) were analyzed.

Results: The pCR rate was higher in patients with negative hormone receptors and this difference was statistically significant (p:0.000). The rate of obtaining pCR increased as the NACT duration increased, and this increase was statistically significant. The mean NACT duration applied to the patients with pCR was 5.48 ± 0.22 months, and the mean NACT duration for those who could not obtain pCR was 5.01 ± 0.1 months (p:0.041). The recurrence rate of patients with pCR was 11.1%, while the recurrence rate of patients who could not obtain pCR was 31.6% (p:0.04).

Conclusions: Pathological response to chemotherapy is an important factor in determining prognosis. There appears to be a need for new biomarkers that allow the prediction of pCR and long-term outcomes.

Metrics

Metrics Loading ...

References

C. Fitzmaurice et al., “Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study global burden o,” JAMA Oncol., vol. 4, no. 11, pp. 1553–1568, 2018, doi: 10.1001/jamaoncol.2018.2706.

D. Simos, M. Clemons, O. M. Ginsburg, and C. Jacobs, “Definition and consequences of locally advanced breast cancer,” Curr. Opin. Support. Palliat. Care, vol. 8, no. 1, pp. 33–38, 2014, doi: 10.1097/SPC.0000000000000020.

P. Cortazar and C. E. Geyer, “Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer,” Ann. Surg. Oncol., vol. 22, no. 5, pp. 1441–1446, 2015, doi: 10.1245/s10434-015-4404-8.

F. Cardoso et al., “Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Ann. Oncol., vol. 30, no. 8, pp. 1194–1220, 2019, doi: 10.1093/annonc/mdz173.

T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, “Türkiye Kanser İstatistikleri 2016,” 2019. [Online]. Available: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/Trkiye_Kanser_statistikleri_2016.pdf.

M. Sawaki, T. Shien, and H. Iwata, “TNM classification of malignant tumors (Breast Cancer Study Group),” Jpn. J. Clin. Oncol., vol. 49, no. 3, pp. 228–231, 2019, doi: 10.1093/jjco/hyy182.

B. O. Anderson et al., “Guideline implementation for breast healthcare in low-income and middle-income countries: Overview of the breast health global initiative Global Summit 2007,” Cancer, vol. 113, no. 8 SUPPL., pp. 2221–2243, 2008, doi: 10.1002/cncr.23844.

N. Güler et al., “2010 İ STANBUL MEME KANSERİ KONSENSUS TOPLANTISI CONSENSUS MEETING,” pp. 68–89, 2011.

J. Klein et al., “Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: A retrospective cohort analysis,” BMC Cancer, vol. 19, no. 1, pp. 1–11, 2019, doi: 10.1186/s12885-019-5499-2.

B. K. Killelea et al., “Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: Results from the national cancer database,” J. Am. Coll. Surg., vol. 220, no. 6, pp. 1063–1069, 2015, doi: 10.1016/j.jamcollsurg.2015.02.011.

P. Rastogi et al., “Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27,” J. Clin. Oncol., vol. 26, no. 5, pp. 778–785, 2008, doi: 10.1200/JCO.2007.15.0235.

M. Trudeau, S. E. Sinclair, and M. Clemons, “Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: A systematic review,” Cancer Treat. Rev., vol. 31, no. 4, pp. 283–302, 2005, doi: 10.1016/j.ctrv.2005.03.007.

S. M. Swain et al., “Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study,” Lancet Oncol., vol. 14, no. 6, pp. 461–471, 2013, doi: 10.1016/S1470-2045(13)70130-X.

C. Allemani et al., “Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2),” Lancet, vol. 385, no. 9972, pp. 977–1010, 2015, doi: 10.1016/S0140-6736(14)62038-9.

F. Affecting et al., “Lokaİleri̇ MemeKanserli̇ Olgularda NeoadjuvanKemoterapi̇ Sonrasi Hastaliksiz Ve Genel SağkalimiEtki̇leyen Faktörler Uzun Dönem Sonuçlarimiz,” J. breast Heal., vol. 8, no. 3, pp. 138–145, 2012.

L. Spring et al., “Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer,” JNCCN J. Natl. Compr. Cancer Netw., vol. 15, no. 10, pp. 1216–1223, 2017, doi: 10.6004/jnccn.2017.0158.

A. E. Ring, I. E. Smith, S. Ashley, L. G. Fulford, and S. R. Lakhani, “Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer,” Br. J. Cancer, vol. 91, no. 12, pp. 2012–2017, 2004, doi: 10.1038/sj.bjc.6602235.

Y. R. Park et al., “Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer,” Asian J. Surg., vol. 43, no. 3, pp. 467–475, 2020, doi: 10.1016/j.asjsur.2019.05.010.